EPO: Cost-Effectiveness
Optimal target hematocrit range is still controversial
Achieving a normal hematocrit (~42%) may not be beneficial in ESRD patients with preexisting cardiac disease, however, certain dialysis patients may have improved quality of life (QOL) at higher hematocrits.
Besarb A et al. N Engl J Med 1998;339:584-90
Moreno F et al. J Am Soc Nephrol 2000;11:335-342